公开(公告)号：US20070172520A1

公开(公告)日：2007-07-26

申请号：US11561639

申请日：2006-11-20

申请人： Michael VanAuker ,  Anna Plaas ,  Elizabeth Hood

发明人： Michael VanAuker ,  Anna Plaas ,  Elizabeth Hood

IPC分类号： A61K39/395 ,  A61K9/127

CPC分类号： A61K39/00 ,  A61K9/1272 ,  A61K39/44 ,  A61K47/6913

摘要： An immunoniosmes for targeted delivery of therapeutic agents to specific tissues in a host and methods of synthesis of those niosomes. An antibody molecule having specificity for a target antigen, such as a cell surface marker or other marker differentially expressed on a target cell, is covalently coupled to a functionalized membrane constituent. In a particular embodiment the functionalized membrane constituent is polyoxyethylene sorbitan monostearate functionalized with cyanuric chloride. The niosomes of this invention thus provide a composition that enhances internalization or retention of the bioactive agent of the niosome into the cytoplasm of the cells of the target tissue by providing a high degree of target specificity. Furthermore, the membrane vesicle enhances the life of the therapeutic agent by preventing its degradation in the extracellular environment, while exhibiting lower toxicity than can occur with some liposomes. The niosomes of the present invention are thus particularly useful as vehicles for the delivery of therapeutics to specific target cells.

摘要翻译： 将治疗剂靶向递送到宿主中的特定组织的免疫组织和合成这些niosomes的方法。 对靶抗原（例如细胞表面标志物或靶细胞上差异表达的其他标记物）具有特异性的抗体分子与官能化的膜成分共价偶联。 在一个具体实施方案中，官能化膜组分是用氰尿酰氯官能化的聚氧乙烯脱水山梨醇单硬脂酸酯。 因此，本发明的niosomes提供了一种组合物，其通过提供高度的靶特异性来增强niosome的生物活性剂的内化或保留到靶组织的细胞的细胞质中。 此外，膜囊泡通过防止其在细胞外环境中的降解来增强治疗剂的寿命，同时表现出比一些脂质体可能发生的毒性更低的毒性。 因此，本发明的niosomes特别可用作将治疗剂递送到特定靶细胞的载体。